{
  "id": "mhgap#referral_52a258b3",
  "content": "throughout the world, second-generation and other\nPSY3. In adults with bipolar disorder in remission, how long should\nantipsychotic medicine or mood stabilizers be continued after\nremission in order to allow for the best outcomes?\nRecommendation (update): Maintenance therapy with mood stabilizers or antipsychotic medicines\nshould be considered for at least six months for adults with bipolar\ndisorder in remission, carefully balancing effectiveness, side-effects and\nindividual preference.\nStrength of recommendation: Conditional\nCertainty of evidence: Low\nJustification Thoma et al., 2018 (596 RCTs on second-generation\ny Evidence was extracted from three systematic antipsychotic medicines and short-term mortality in\nreviews: Kishi et al., 2021 (22 RCTs comparing individuals with severe mental illness) (193).\nbetween antipsychotic/mood stabilizer y The anticipated desirable effects for maintenance\ndiscontinuation and maintenance groups in therapy are moderate to large for recurrence rate\nindividuals with bipolar disorder) (195); Kishi et of any mood episode/depressive episode/manic,\nal., 2021 (41 RCTs on antipsychotics and/or mood hypomanic or mixed episode at different time\nstabilizers for individuals with bipolar disorder points. Most data were available for a follow-up of up\nin the maintenance phase) (196); and Schneider- to six months.\n90\n3. Recommendations",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Referral throughout the world, second-generation and other\nPSY3. In adults with bipolar disorder in remission, how long should\nantipsychotic medicine or mood stabilizers be continued after\nremission in order to allow for the best outcomes?\nRecommendation (update): Maintenance therapy with mood stabilizers or antipsychotic medicines\nshould be considered for at least six months for adults with bipolar\ndisorder in remission, carefully balancing effectiveness, side-effects and\nindividual preference.\nStrength of recommendation: Conditional\nCertainty of evidence: Low\nJustification Thoma et al., 2018 (596 RCTs on second-generation\ny Evidence was extracted from three systematic antipsychotic medicines and short-term mortality in\nreviews: Kishi et al., 2021 (22 RCTs comparing individuals with severe mental illness) (193).\nbetween antipsychotic/mood stabilizer y The anticipated desirable effects for maintenance\ndiscontinuation and maintenance groups in therapy are moderate to large for recurrence rate\nindividuals with bipolar disorder) (195); Kishi et of any mood episode/depressive episode/manic,\nal., 2021 (41 RCTs on antipsychotics and/or mood hypomanic or mixed episode at different time\nstabilizers for individuals with bipolar disorder points. Most data were available for a follow-up of up\nin the maintenance phase) (196); and Schneider- to six months.\n90\n3. Recommendations Throughout the world, second-generation and other\npsy3. in adults with bipolar disorder in remission, how long should\nantipsychotic medicine or mood stabilizers be continued after\nremission in order to allow for the best..."
}